SCHEMBL17747032

SCHEMBL17747032

[N-]=[N+]=NCCOCCOCCOCCNC(=O)C[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.44
▸ EPHX2 P34913 2/20 0.38
▸ FOLH1 Q04609 8/20 0.36
▸ TTR P02766 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19990741 1.00 GLP1R (0.44) GLP1REPHX2FOLH1TTR
SCHEMBL17747012 1.00 GLP1R (0.44) GLP1REPHX2FOLH1TTR
SCHEMBL19990825 1.00 GLP1R (0.44) GLP1REPHX2FOLH1TTR
SCHEMBL17747047 0.90 GLP1R (0.55) GLP1RFOLH1
SCHEMBL17747022 0.90 GLP1R (0.55) GLP1RFOLH1
SCHEMBL17747024 0.90 GLP1R (0.55) GLP1RFOLH1
SCHEMBL19990821 0.90 GLP1R (0.55) GLP1RFOLH1
SCHEMBL17747058 0.90 GLP1R (0.55) GLP1RFOLH1
SCHEMBL21866606 0.90 GLP1R (0.55) GLP1RFOLH1
SCHEMBL19990740 0.90 GLP1R (0.55) GLP1RFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952434-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-09 — — US disclosed
US-20230101323-A1 IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-03-30 — — US disclosed
US-11358988-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2022-06-14 — — US disclosed
EP-3778622-A1 MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2021-02-17 — — EP disclosed
EP-3218392-B1 MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2020-07-29 — — EP disclosed
US-20200216498-A1 IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-07-09 — — US disclosed
US-10633419-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-04-28 — — US disclosed
US-20180086793-A1 IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2018-03-29 — — US disclosed
US-9856292-B2 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-02 — — US disclosed
EP-3218392-A1 MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS Bristol-Myers Squibb Company (US) 2017-09-20 — — EP disclosed
US-20160137696-A1 Immunomodulators BRISTOL-MYERS SQUIBB COMPANY 2016-05-19 — — US disclosed
WO-2016077518-A1 MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11952434-B2 Immunomodulators CD74, ICOS, HAVCR2 GLP1R 4424/4885EPHX2 2816/4885FOLH1 550/4885
US-20160137696-A1 Immunomodulators CD74, ICOS, HAVCR2 GLP1R 4424/4885EPHX2 2816/4885FOLH1 550/4885
US-20230101323-A1 IMMUNOMODULATORS CD74, ICOS, HAVCR2 GLP1R 4424/4885EPHX2 2816/4885FOLH1 550/4885
US-10633419-B2 Immunomodulators CD74, ICOS, HAVCR2 GLP1R 4424/4885EPHX2 2816/4885FOLH1 550/4885
US-11358988-B2 Immunomodulators CD74, ICOS, HAVCR2 GLP1R 4424/4885EPHX2 2816/4885FOLH1 550/4885
US-20180086793-A1 IMMUNOMODULATORS CD74, ICOS, HAVCR2 GLP1R 4424/4885EPHX2 2816/4885FOLH1 550/4885
US-20200216498-A1 IMMUNOMODULATORS CD74, ICOS, HAVCR2 GLP1R 4424/4885EPHX2 2816/4885FOLH1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback